Literature DB >> 17622527

HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention.

Malcolm Taylor1, Christine Harrison, Tim Eden, Jillian Birch, Mel Greaves, Tracy Lightfoot, Adiba Hussain.   

Abstract

Most childhood B cell precursor (BCP) acute lymphoblastic leukaemia (ALL) cases carry the reciprocal translocation t(12;21)(p13;q22) ( approximately 25%), or a high hyperdiploid (HeH) karyotype (30%). The t(12;21) translocation leads to the expression of a novel fusion gene, TEL-AML1 (ETV6-RUNX1), and HeH often involves tri- and tetrasomy for chromosome 21. The presence of TEL-AML1+ and HeH cells in utero prior to the development of leukaemia suggests that these lesions play a critical role in ALL initiation. Based on our previous analysis of HLA-DP in childhood ALL, and evidence from in vitro studies that TEL-AML1 can activate HLA-DP-restricted T cell responses, we hypothesised that the development of TEL-AML1+ ALL might be influenced by the child's DPB1 genotype. To test this, we analysed the frequency of six HLA-DPB1 supertypes in a population-based series of childhood leukaemias (n = 776) classified by their karyotype (TEL-AML1+, HeH and others), in comparison with newborn controls (n = 864). One DPB1 supertype (GKD) conferred significant protection against TEL-AML1+ ALL (odds ratio (OR), 95% confidence interval (95% CI): 0.42, 0.22-0.81; p < 0.005) and HeH ALL (OR; 95% CI: 0.44, 0.30-0.65; p < 0.0001). These negative associations were almost entirely due to a single allele, DPB1*0101. Our results suggest that DPB1*0101 may afford protection from the development of TEL-AML1+ and HeH BCP ALL, possibly as the result of a DP-restricted immune response to BCP ALL-associated antigen(s), the identification of which could have important implications for the design of prophylactic vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622527     DOI: 10.1007/s00262-007-0349-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

1.  HLA-DP genetic variation, proxies for early life immune modulation and childhood acute lymphoblastic leukemia risk.

Authors:  Kevin Y Urayama; Anand P Chokkalingam; Catherine Metayer; Xiaomei Ma; Steve Selvin; Lisa F Barcellos; Joseph L Wiemels; John K Wiencke; Malcolm Taylor; Paul Brennan; Gary V Dahl; Priscilla Moonsamy; Henry A Erlich; Elizabeth Trachtenberg; Patricia A Buffler
Journal:  Blood       Date:  2012-08-24       Impact factor: 22.113

2.  Genetic variation in the folate metabolic pathway and risk of childhood leukemia.

Authors:  Tracy J Lightfoot; W Thomas Johnston; Dan Painter; Jill Simpson; Eve Roman; Chris F Skibola; Martyn T Smith; James M Allan; G Malcolm Taylor
Journal:  Blood       Date:  2010-01-25       Impact factor: 22.113

Review 3.  Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework.

Authors:  Oskar A Haas
Journal:  Front Immunol       Date:  2019-02-12       Impact factor: 7.561

4.  HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial.

Authors:  G M Taylor; R Wade; A Hussain; P Thompson; I Hann; B Gibson; T Eden; S Richards
Journal:  Blood Cancer J       Date:  2012-07-20       Impact factor: 11.037

5.  HLA-associated susceptibility to childhood B-cell precursor ALL: definition and role of HLA-DPB1 supertypes.

Authors:  G M Taylor; A Hussain; T J Lightfoot; J M Birch; T O B Eden; M F Greaves
Journal:  Br J Cancer       Date:  2008-03-11       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.